Akintunde Bello

Director/Board Member at XILIO THERAPEUTICS, INC.

64 year

Consumer Services

Health Technology

Profile

Akintunde Bello is currently Director at Xilio Therapeutics, Inc. since 2025.
Formerly, Dr. Bello was SVP, Head-Pharmacology & Bioanalysis at Bristol Myers Squibb Co. Education includes a doctorate from King's College London, a graduate degree from The University of Manchester, and an undergraduate degree from the University of Portsmouth.

Akintunde Bello active positions

Companies	Position	Start
XILIO THERAPEUTICS, INC.	Director/Board Member	10/06/2025

All active positions of Akintunde Bello

Former positions of Akintunde Bello

Companies	Position	End
BRISTOL-MYERS SQUIBB COMPANY	Corporate Officer/Principal	01/01/2025

See the detail of Akintunde Bello's experience

Training of Akintunde Bello

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Akintunde Bello's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Bristol Myers Squibb Co. Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products	Health Technology
The University of Manchester The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Portsmouth University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
King's College London King's College London Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Xilio Therapeutics, Inc. Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies	Health Technology